Andrew Burch - 31 Dec 2023 Form 5 Insider Report for MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)

Role
President, Nucleic Acid Production
Signature
/s/ Kurt Oreshack, by power of attorney for Andrew Burch
Issuer symbol
MRVI
Transactions as of
31 Dec 2023
Net transactions value
$0
Form type
5
Filing time
18 Jan 2024, 18:15:20 UTC
Previous filing
06 Apr 2023
Next filing
18 Jan 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRVI Class A Common Stock Award +141,011 141,011 17 Apr 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRVI Employee Stock Options (Right to Buy) Award $0 +80,000 $0.000000 80,000 17 Apr 2023 Class A Common Stock 80,000 $14.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs") awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. Each RSU represents the right to receive one share of Class A Common Stock of the Issuer upon vesting. The RSUs will vest in 1/3rd increments on each of April 15, 2024, April 15, 2025, and April 15, 2026, subject to the Reporting Person's continued employment with the Issuer.
F2 Represents options awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. These options will vest 25% on April 15, 2024 and in equal 1/48th installments each month thereafter, subject to the Reporting Person's continued employment with the Issuer.

Remarks:

President, Nucleic Acid Production